Dr. Nicholas DiBella

Claim this profile

Rocky Mountain Cancer Centers-Boulder

Expert in Cancer
Expert in Breast Cancer
103 reported clinical trials
193 drugs studied

About Nicholas DiBella

Education:

  • Earned a Medical degree (MD) from an unspecified institution.

Experience:

  • Founded Rocky Mountain Cancer Centers (RMCC) in 1992 and served as its former president.
  • Served as Chairman of the Board for the Colorado Cancer Research Program.
  • Held the position of Chairman for the US Oncology Hematology Research Committee.
  • Played a key role in establishing The US Oncology Network, connecting over 1,400 oncologists nationwide.
  • Retired as Medical Director at Rocky Mountain Breast Specialists.

Area of expertise

1Cancer
Global Leader
Nicholas DiBella has run 43 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Nicholas DiBella has run 20 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 positive
Stage II

Affiliated Hospitals

Image of trial facility.
Rocky Mountain Cancer Centers-Boulder
Image of trial facility.
Rocky Mountain Cancer Centers-Aurora

Clinical Trials Nicholas DiBella is currently running

Image of trial facility.

Financial Navigation

for Cancer Patients

This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, education and connections to appropriate resources to reduce financial barriers to healthcare and minimize financial stress and burden. CostCOM may improve adherence to care and decrease financial burden in patients with cancer.
Recruiting1 award N/A
Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria

More about Nicholas DiBella

Clinical Trial Related5 years of experience running clinical trials · Led 103 trials as a Principal Investigator · 53 Active Clinical Trials
Treatments Nicholas DiBella has experience with
  • Nivolumab
  • Pembrolizumab
  • Cisplatin
  • Atezolizumab
  • Fluorouracil
  • Intensity-Modulated Radiation Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nicholas DiBella specialize in?
Nicholas DiBella focuses on Cancer and Breast Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Nicholas DiBella currently recruiting for clinical trials?
Yes, Nicholas DiBella is currently recruiting for 50 clinical trials in Boulder Colorado. If you're interested in participating, you should apply.
Are there any treatments that Nicholas DiBella has studied deeply?
Yes, Nicholas DiBella has studied treatments such as Nivolumab, Pembrolizumab, Cisplatin.
What is the best way to schedule an appointment with Nicholas DiBella?
Apply for one of the trials that Nicholas DiBella is conducting.
What is the office address of Nicholas DiBella?
The office of Nicholas DiBella is located at: Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado 80304 United States. This is the address for their practice at the Rocky Mountain Cancer Centers-Boulder.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.